Choose ALUNBRIG® (brigatinib): A Well-Established Safety Profile
Adverse Reactions in ≥10% (All Gradesa) or ≥2% (Grades 3-4) of Patients by Arm in ALTA 1L (N=273)1
Serious adverse reactions occurred in 33% of patients receiving ALUNBRIG.1
The most common serious adverse reactions in ALTA 1L were pneumonia (4.4%), ILD/pneumonitis (3.7%), pyrexia (2.9%), dyspnea (2.2%), pulmonary embolism (2.2%), and asthenia (2.2%). Fatal adverse reactions occurred in 2.9% of patients and included pneumonia (1.5%), cerebrovascular accident (0.7%), and multiple organ dysfunction syndrome (0.7%).1
Laboratory Abnormalities in ≥20% (All Gradesa) of Patients by Arm in ALTA 1L (N=273)1
Interstitial lung disease/pneumonitis1
- In the first-line phase 3 trial, ILD/pneumonitis occurred in 5.1% of patients receiving ALUNBRIG, with Grade 3 or 4 reactions occurring in 2.2% of patients1
- In the post-crizotinib phase 2 trial (ALTA): ILD/pneumonitis occurred in 9.1% of patients, in the 90→180 mg arm. Adverse reactions consistent with ILD/pneumonitis occurred in 6.4% of patients, with Grade 3 or 4 reactions occurring in 2.7% of patients1
Long-Terma Tolerability in ALTA 1L1
- Median duration of treatment with ALUNBRIG: 24.3 months
- Median relative dose intensity with ALUNBRIG: 97%
Dose reductions occurred in 38% of patients receiving ALUNBRIG.1
The most common adverse reactions in ALTA 1L that led to dose reduction were increased creatine phosphokinase (15%), increased lipase (6.6%), increased amylase (4.4%), increased aspartate aminotransferase (2.2%), ILD/pneumonitis (2.2%), and hypertension (2.2%).1
Permanent discontinuation due to adverse reactions occurred in 13% of patients receiving ALUNBRIG.1
The most frequent adverse reactions in ALTA 1L that led to discontinuation were ILD/pneumonitis (3.7%) and pneumonia (2.2%).1
aBased on the median follow-up in the ALUNBRIG arm of ALTA 1L of 40.4 months.2 ILD, interstitial lung disease.
Patient Brochure
Download patient-friendly information to help patients understand their treatment with ALUNBRIG